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Anti-angiogenesis Effect of the Novel Anti-inflammatory
and Pro-resolving Lipid Mediators
Yiping Jin,1,2 Makoto Arita,3 Qiang Zhang,1,2 Daniel R. Saban,1,2 Sunil K. Chauhan,1,2
Nan Chiang,3 Charles N. Serhan,3 and Reza Dana1,2
PURPOSE. Resolvins and lipoxins are lipid mediators generated
from essential polyunsaturated fatty acids that are the first dual
anti-inflammatory and pro-resolving signals identified in the
resolution phase of inflammation. Here the authors investi-
gated the potential of aspirin-triggered lipoxin (LX) A4 analog
(ATLa), resolving (Rv) D1, and RvE1, in regulating angiogenesis
in a murine model.
METHODS. ATLa and RvE1 receptor expression was tested in
different corneal cell populations by RT-PCR. Corneal neovas-
cularization (CNV) was induced by suture or micropellet (IL-
1, VEGF-A) placement. Mice were then treated with ATLa,
RvD1, RvE1, or vehicle, subconjunctivally at 48-hour intervals.
Infiltration of neutrophils and macrophages was quantified
after immunofluorescence staining. The mRNA expression lev-
els of inflammatory cytokines, VEGFs, and VEGFRs were ana-
lyzed by real-time PCR. CNV was evaluated intravitally and
morphometrically.
RESULTS. The receptors for LXA4, ALX/Fpr-rs-2 and for RvE1,
ChemR23 were each expressed by epithelium, stromal kerato-
cytes, and infiltrated CD11b cells in corneas. Compared to
the vehicle-treated eye, ATLa-, RvD1-, and RvE1-treated eyes
had reduced numbers of infiltrating neutrophils and macro-
phages and reduced mRNA expression levels of TNF-, IL-1,
IL-1, VEGF-A, VEGF-C, and VEGFR2. Animals treated with
these mediators had significantly suppressed suture-induced or
IL-1–induced hemangiogenesis (HA) but not lymphangiogen-
esis. Interestingly, only the application of ATLa significantly
suppressed VEGF-A–induced HA.
CONCLUSIONS. ATLa, RvE1, and RvD1 all reduce inflammatory
corneal HA by early regulation of resolution mechanisms in
innate immune responses. In addition, ATLa directly inhibits
VEGF-A–mediated angiogenesis and is the most potent inhibi-
tor of NV among this new genus of dual anti-inflammatory and
pro-resolving lipid mediators. (Invest Ophthalmol Vis Sci.
2009;50:4743–4752) DOI:10.1167/iovs.08-2462
The normal cornea has no blood or lymphatic vessels. Thisfeature is essential for corneal transparency and optimal
visual performance and contributes to the immunologic privi-
lege of the cornea. Neovascularization (NV) is a common
complication secondary to various corneal diseases, including
infection, degeneration, trauma, and stem cell deficiency–in-
duced insults. NV is also strongly associated with graft failure
after corneal transplantation. Additionally, CNV (CNV) as a
result of viral or chlamydial (trachoma) infection is a leading
cause of visual impairment worldwide.
CNV is a complex response to a number of stimuli and
involves a sequence of coordinated cellular and molecular
mechanisms. Dilation of the existing limbal vessels followed by
adhesion and diapedesis of leukocytes, such as neutrophils and
macrophages, and migration and proliferation of vascular en-
dothelial cells (ECs), in large part mediated by vascular endo-
thelial growth factor (VEGF), are all important factors in NV
pathogenesis.1–3
Treatment with omega-3 polyunsaturated fatty acids
(PUFAs), such as eicosapentaenoic acid (EPA) and docosa-
hexaenoic acid (DHA), is known to be beneficial in a wide
range of inflammatory disorders. More recently, the potential
efficacy of omega-3 PUFA in the inhibition of tumor angiogen-
esis has been demonstrated.4 A novel genus of potent anti-
inflammatory and pro-resolving lipid mediators biosynthesized
from PUFA includes three unique families: lipoxins/aspirin-
triggered lipoxin (ATL) derived from arachidonic acid, re-
solvins of the D-series (RvDs) from DHA, and resolvins of the
E-series (RvEs) from EPA. Recent findings indicate that these
lipid mediators are produced actively during the resolution
phase of inflammation to reestablish normal homeostasis. Spe-
cifically, prostaglandin E2 and prostaglandin D2 stimulate the
switching of arachidonic acid–derived lipids from leukotriene
B4 production to lipoxin A4 production and the switching of
lipid mediator families to produce anti-inflammatory and pro-
resolution lipid mediators, such as RvDs and RvEs. Lipoxin A4,
RvD1, and RvE1, the endogenous natural compounds, promote
the resolution of exudates and display potent anti-inflammatory
and immunoregulatory functions.5 These actions include re-
ducing neutrophil trafficking and regulating reactive oxygen
species.6,7 Although the contribution of these lipid mediators
in the resolution of inflammation and maintenance of ho-
meostasis has been established in several disease models,8–13
their relative efficacy in the modulation of angiogenesis has not
been investigated systematically. In this study, we report that
resolvin D1 (RvD1), resolvin E1 (RvE1), and a stable analog of
aspirin-triggered lipoxin A4 (ATLa) significantly downregulate
the expression of angiogenic growth factors and their recep-
tors and the infiltration of neutrophils and macrophages con-
comitant with the suppression of inflammatory cytokines.
These changes have a significantly greater effect in reducing
hemangiogenesis (HA) than lymphangiogenesis (LA).
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METHODS
Animals
Six- to 8-week-old male BALB/c (Taconic Farms, Germantown, NY)
mice were used in all experiments. All experimental protocols were
approved by the Schepens Eye Research Institute Animal Care and Use
Committee, and all animals were treated according to the ARVO State-
ment for the Use of Animals in Ophthalmic and Vision Research.
Suture-Induced Inflammatory
Corneal Angiogenesis
Our standard model for the induction of inflammatory CNV is associ-
ated with the development of intrastromal vessels in close association
with a mixed-cell (primarily neutrophilic) infiltrate.14,15 Three inter-
rupted sutures (11-0 nylon; Sharpoint; Vanguard, Houston, TX) were
placed intrastromally with two stromal incursions extending over 120°
of the corneal circumference to induce inflammatory CNV, which is
also associated with significant LA, as described.14 The corneas were
followed by slit lamp biomicroscopy for CNV development. NV was
graded between 0 and 3, with increments of 0.5, using a grid system
per each corneal quadrant based on the centripetal extent of the
neovascular branches from the limbus. Scores for each quadrant were
then summed to derive the NV index (range, 0–12) for each eye, as
previously described.14
Corneal Micropocket Assay
The corneal micropocket assay in mice and quantification of the
resultant NV has been described previously.16,17 In brief, 0.3 L hy-
dron pellets (IFN Sciences, New Brunswick, NJ) containing 30 ng
murine IL-1 (R&D Systems, Minneapolis, MN) or 200 ng VEGF-A (gift
from BRB Preclinical Repository, National Cancer Institute) were pre-
pared and implanted into the corneal stroma of male BALB/c mice.
After 7 days, the animals were killed and the corneas were harvested
for quantitative analysis of HA and LA.
Ocular Administration of Compounds
BALB/c mice were randomized to receive ATLa, RvD1, RvE1, or vehicle
(normal saline) by subconjunctival injection in a masked fashion after
suture or hydron pellet placement. The compounds were administered
at a dose of 100 ng/10 L per mouse every 48 hours after suture or
pellet placement. For these experiments, RvD1 and RvE1 were pre-
pared by total organic synthesis, as reported previously,18,19 in the total
organic synthesis core for NIH P50 DE0169191. ATLa was synthesized
as described previously.20 Physical properties were monitored rou-
tinely by liquid chromatography coupled to tandem mass spectrometry
matching the reported biological and physical properties before anal-
ysis in the present experiments.
RNA Isolation and RT-PCR
Corneas were carefully dissected to ensure that the conjunctival and
iris tissues were not included. To extract mRNA from whole-thickness
corneas, two corneas were pooled as a sample in each group. To
extract mRNA from corneal epithelial and stroma-endothelial layers
separately, intact corneas were placed in 30 L RNA stabilization
reagent (RNAlater; Qiagen, Valencia, CA) at 4°C overnight and then
were stored at30°C for 2 to 3 days. After they were incubated in 250
L of 20 mM EDTA (sterile, pH 7.4) at 37°C for 30 minutes, the
epithelial layers were peeled from the stroma-endothelial layers before
mRNA isolation. Ten corneal epithelial layers or stromal-endothelial
layers were pooled as a sample in each group. The mRNA isolated from
submandibular lymph nodes was used as a positive control.
A combined-method for total RNA isolation was used with reagent
(Trizol; Invitrogen Corp., Carlsbad, CA) and spin columns (RNeasy
MinElute; Qiagen, Valencia, CA), as described previously.21 Reverse tran-
scription of total RNA was conducted using oligo(dT)20 primer and re-
verse transcriptase (Superscript III; Invitrogen, Carlsbad, CA). PCR was
conducted using primer pairs for Fprl1 (sense, GATGCTAGAGGGGATGT-
GCAC; antisense, TCTTCAGGAAGTGAAGCC; 530 bp), Fpr-rs2 (sense,
TGCTGTCAAGATCAACAGAAG; antisense, TGCCAGGAGGTGAAGTA-
GAAC; 359 bp), ChemR23 (sense, ACCACACCCTCTACCTGCTG; anti-
sense, TGGTGAAGCTCCTGTGACTG; 237 bp), and GAPDH (sense,
GAAGGGCATCTTGGGCTACAC; antisense, GCAGCGAACTTTATTGATG-
GTATT; 373 bp). PCR conditions were 35 cycles at 95°C for 30 seconds,
56°C for 30 seconds, and 72°C for 1 minute, followed by final extension
at 72°C for 10 minutes. PCR products were observed by agarose gel
electrophoresis. The mean density of each band was measured with
ImageJ software (developed by Wayne Rasband, National Institutes of
Health, Bethesda, MD; available at http://rsb.info.nih.gov/ij/index.html).
The density of each receptor band was divided by the density of the
corresponding GAPDH band to obtain the normalized band density.
Real-Time PCR
One microliter total cDNA, synthesized from 400 ng total RNA with
random hexamers using reverse transcriptase (Superscript III; Invitrogen,
Carlsbad, CA), was loaded in each well, and assays were performed in
triplicate. Quantitative PCRwas performedwith PCRmaster mix (TaqMan
Universal; Applied Biosystems, Foster City, CA) and dye-labeled prede-
signed primers (FAM-MGB; Applied Biosystems) for IL-1 (Mm
99999060_ml), TNF- (Mm99999068_ml), IL-1 (Mm00434228_ml),
VEGFR2 (Mm00440099_ml), VEGFR3 (Mm00433337_ml), VEGFA
(Mm00437304_ml), and VEGFC (Mm00437313_ml). PCR conditions
were 2 minutes at 50°C, 10 minutes at 95°C, followed by 35 cycles of 15
seconds at 95°C and then 1 minute 60°C (ABI PRISM 7900 HT; Applied
Biosystems). PCR amplification of the housekeeping gene encoding
GAPDH (Mm999999915_gl) was performed during each run for each
sample to allow normalization between samples. A nontemplate control
was included in all the experiments to evaluate DNA contamination of
isolated RNA and reagents. Results were analyzed by comparative thresh-
old cycle (CT) method. The relative expression level of each sample was
expressed as fold change from normal control.
Isolation of Cornea-Infiltrating Cells
Forty corneas were pooled, teased with scissors, and digested with
collagenase D (11088874103; Roche Applied Science, Indianapolis, IN)
at 37°C for 1 hour in a humidified atmosphere of 5% CO2. After incuba-
tion, corneas were disrupted by grinding with a syringe plunger.22–24
Total cells were then collected after they were passed through a steel
mesh. On blockade by anti–FcR mAb, these cells were labeled with
FITC-conjugated rat anti–mouse CD11b (granulocyte/monocyte/macro-
phage marker; BD PharMingen, San Diego, CA) at 4°C for 30 minutes.
CD11b cells were sorted from total cells with a high-performance cell
sorter (MoFlo; Cytomation, Fort Collins, CO).
MK/T-1 Cell Culture and Stimulation
MK/T-1 cells, immortalized keratocytes from the corneal stroma of
C57BL/6 mouse (gift from Robert Gendron [Memorial University of
Newfoundland, St. John’s, Newfoundland, Canada]), were used to
identify the expression of lipid mediator receptors on the corneal
keratocytes. MK/T-1 cells were grown in low-glucose Dulbecco mini-
mum essential medium supplemented with 10% fetal bovine serum and
1 mM -glutamine at 37°C in 5% CO2. To stimulate MK/T-1 cells, 10
ng/L TNF- (R&D Systems) and 10 ng/L IL-1 were added to the
culture medium.
Immunohistochemical Studies
Full-thickness corneal tissue or 8-m frozen sections were fixed in
acetone for 15 minutes at room temperature. To block nonspecific
staining, anti–FcR mAb (CD16/CD31, FcIII/II receptor) or 10% goat
serum was used before primary antibodies or isotype-matched control
antibodies were applied at 4°C overnight. Thereafter, samples were
incubated with secondary antibodies at room temperature. Each step
was followed by three thorough washings in PBS for 5 to 10 minutes.
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Finally, the samples were covered with mounting medium (Vector
Laboratories, Burlingame, CA) and analyzed by epifluorescence micros-
copy (Eclipse E800; Nikon, Tokyo, Japan). The following antibodies
were used: FITC-conjugated rat anti–mouse CD31 (Santa Cruz Biotech-
nology, Santa Cruz, CA), purified rat anti–mouse neutrophil (NIMP-
R14; Abcam, Cambridge, MA), purified rat anti–mouse F4/80 (Novus
Biologicals, Littleton, CO), and purified rabbit anti–mouse LYVE-1 (Ab-
cam). Secondary antibodies were rhodamine-conjugated donkey anti–
rabbit IgG and rhodamine-conjugated goat anti–rat IgG (Santa Cruz
Biotechnology). Isotype controls included FITC-conjugated rat IgG2a,
purified rat IgG2b, and purified rabbit IgG (Santa Cruz Biotechnology).
To quantify corneal angiogenesis, digital pictures of corneal flat-
mounts were taken using an image analysis system (Spot Image Anal-
ysis; Diagnostic Instruments, Sterling Heights, MI). The areas covered
by CD31high/LYVE-1low vessels (blood vessels) or CD31lowLYVE-1high
vessels (lymphatics) were measured morphometrically with ImageJ
software (developed by Wayne Rasband, National Institutes of Health,
Bethesda, MD; available at http://rsb.info.nih.gov/ij/index.html). The
total corneal area was outlined using the innermost vessel of the limbal
arcade as the border. Vessel density was calculated by the proportion
of neovascularized area to the whole corneal area.
Statistical Analysis
All data are expressed as mean  SEM. Statistical significance between
the vehicle and each lipid mediator group was analyzed by the two-
tailed t-test (Prism version 4.0; GraphPad, San Diego, CA).
RESULTS
LipoxinA4 and Resolvin E1 Receptor Expression
in the Cornea
We determined the expression of the receptors for ATLa and
RvE1 in corneal tissue by RT-PCR. In the normal corneas,
Fpr-rs2 (one of the murine LXA4 receptors) and ChemR23 (the
RvE1 receptor), but not Fprl1 (another murine LXA4 receptor),
were present in the epithelial and stromal-endothelial layers
(Fig. 1). The receptor for RvD1 has not been identified to date.
To further delineate whether corneal keratocytes versus
immunocytic CD11b cells (i.e., macrophages and dendritic
cells) in the corneal stroma express these receptors, we cul-
tured MK/T-1 cells (an immortalized corneal keratocyte cell
line) stimulated with TNF- and IL-1 to mimic in situ corneal
inflammation. RT-RCR results showed both Fpr-rs2 and
ChemR23 were expressed by MK/T-1 cells irrespective of cy-
tokine stimulation. In addition, the infiltrated CD11b cells,
sorted from the inflamed corneas, also expressed high levels of
Fpr-rs2 and ChemR23 (Fig. 1).
Reduction of Neutrophil and Macrophage
Infiltration by ATLa, RvD1, or RvE1
Next, we treated inflamed corneas with ATLa, RvD1, or RvE1
to assess the action of these lipid mediators on the infiltration
FIGURE 1. Expression of receptors:
Fpr-rs2 and ChemR23 in inflamed
corneas. (A) RT-PCR was used to an-
alyze the expression of Fprl1, Fpr-rs2
(ALX, LXA4 receptors), and ChemR23
(RvE1 receptor). Corneas of normal or
inflamed eyes (10 corneas pooled per
group) were collected, and the epithe-
lium was subsequently separated from
the subjacent stroma-endothelium in
the respective groups. RNA was iso-
lated from these tissues and from MK/
T-1 cells (corneal keratocyte cell line)
with or without TNF- and IL-1 stim-
ulation or FACS-sorted CD11b cells
from inflamed corneas. In addition,
RNA was isolated from lymph nodes
as a positive control. This experiment
was repeated three times. (B) Mean
density of each band was measured by
using ImageJ software (developed by
Wayne Rasband, National Institutes of
Health, Bethesda, MD; available at
http://rsb.info.nih.gov/ij/index.html).
Densities of the Fpr-rs2 and ChemR23
band were normalized with the den-
sity of the corresponding GAPDH
band. Data are shown as a mean of
three experiments, and error bars rep-
resent SEM.
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of neutrophils and macrophages (Fig. 2). Approximately 30%
inhibition of neutrophil recruitment (P  0.05) into the in-
flamed corneas was observed at 24 and 72 hours with the
administration of ATLa (neutrophils: 24 hours, 53  1 cells/
section; 72 hours, 34  5 cells/section; n  3), RvD1 (neutro-
phils: 24 hours, 62  4 cells/section; 72 hours, 40  3 cells/
section; n  3), or RvE1 (neutrophils: 24 hours, 52  4
cells/section; 72 hours, 41  4 cells/section; n  3) compared
with the vehicle-treated group (neutrophils: 24 hours, 81  6
cells/section; 72 hours, 57  4 cells/section; n  3). Similarly,
macrophage infiltration was also reduced, but this was only
observed at 72 hours after suture placement. ATLa (macro-
phage: 46  5 cells/section; n  3), RvD1 (macrophage: 57 
4 cells/section; n  3), or RvE1 (macrophage: 49  7 cells/
section; n  3) resulted in a 25% to 40% (P  0.05) reduction
in macrophage infiltration compared with the vehicle control
group (macrophage: 83  3 cells/section; n  3).
Reduction of Inflammatory Cytokine Expression
by ATLa, RvD1, or RvE1
The mRNA levels of inflammatory cytokines IL-1, IL-1, and
TNF- were monitored by real-time PCR at 24 hours and 72
hours after suture placement (Fig. 3). Treatment with ATLa,
RvD1, or RvE1 led to greater than 50% reduction in the in-
crease of IL-1 expression levels compared with vehicle-
treated controls (P  0.05) after the induction of corneal
inflammation. Increases in TNF- expression were also signif-
icantly suppressed by these three mediators at 24 hours, but
not at 72 hours, except for RvE1 application, which led to a
significant lowering of TNF- expression at 72 hours. The
expression of IL-1 was not significantly altered by these lipid
mediators (Fig. 3). We also confirmed the protein levels of
inflammatory cytokine IL-1 using ELISA in the different treat-
ment groups. As with RNA levels, the ATLa-treated group
showed a 70% decrease in IL-1 protein level compared with
the vehicle-treated group (P  0.001; data not shown).
Impact of ATLa, RvD1, or RvE1 on the Expression
of VEGFs and VEGFRs
To determine the effect of ATLa, RvD1, and RvE1 in the
modulation of angiogenesis, we measured mRNA expression
for the critical ligands (VEGF-A, -C, -D) and receptors (VEGFR-2,
-3) involved in angiogenesis (Fig. 4). In contrast to the vehicle-
treated group, ATLa, RvD1, and RvE1 application groups uni-
formly had lower mRNA expressions of the angiogenic growth
factors VEGF-A,VEGF-C, and their receptor, VEGFR-2, at 24
hours and 72 hours after suture placement. However, mRNA
expression for the lymphangiogenic growth factor VEGF-D and
its receptor VEGFR-3 were not significantly altered in the ATLa,
RvD1, or RvE1 groups compared with vehicle-treated controls.
Evaluation of Clinical CNV and Histologic
Assessment of HA and LA
We measured the growth of corneal neovessels over a 2-week
period by slit lamp biomicroscopy. Use of corneal sutures in
this model induces inflammatory NV within 2 days and peaks
approximately 2 weeks after manipulation, as described previ-
ously.14 We observed that application with any of the three
lipid mediators led to significant suppression of the angiogenic
response compared with the vehicle control (Fig. 5). We fur-
ther compared the density of blood vessels (BVs) and lym-
phatic vessels (LVs) using wholemounted corneas harvested
from the different groups, and costained these with anti–CD31
and anti–LYVE-1 (BVs are CD31high/LYVE-1low, whereas LVs
are CD31lowLYVE-1high). Consistent with our slit lamp obser-
vations, by day 14 after suture placement, the BV density was
significantly suppressed with ATLa (8.26%  0.63%; n  6),
RvD1 (8.4%  0.39%; n  6), or RvE1 (10.92%  0.53%; n 
6) application compared with vehicle application (23.18% 
1.12%; n 6). Interestingly, we did not observe any significant
changes in the density of lymphatic vessels among the lipid
mediator groups compared with the vehicle controls.
ATLa, RvD1, or RvE1 Regulation of IL- and
VEGF-A–Induced HA
To further dissect the direct regulatory actions of these lipid
mediators on VEGF-A-induced angiogenesis compared with a
more indirect inhibitory effect on angiogenesis by the suppres-
sion of innate immune responses, we measured HA and LA
after intrastromal placement of micropellets loaded with IL-1
or VEGF-A. Quantitative analysis of corneal flatmounts har-
FIGURE 2. Resolvins and lipoxin re-
duce neutrophil and macrophage in-
filtration in inflamed corneas. ATLa,
RvD1, RvE1, or vehicle was subcon-
junctivally injected at 0 hour and 48
hours after suture placement. For each
compound treatment, eyes were enu-
cleated from a group of mice at 24
hours and from another group at 72
hours after suture placement (three
eyes per group). Cross-sections were
stained with anti–neutrophil (NIMP-
R14) or anti–macrophage (F4/80) an-
tibody, and 12 sections were used to
enumerate the respective leukocyte
populations. Results represent the
mean ( SEM) of three eyes per group
(*P  0.05, **P  0.001 vs. vehicle-
treated group; t-test), and data are rep-
resentative of two independent exper-
iments.
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vested from VEGF-A micropellet stimulation showed that BV
density in the group treated with ATLa (5.9%  0.4%; n  4),
but not in the group treated with RvD1 (10.9%  2.3%; n  4)
or RvE1 (14.1%  2.2%; n  4), was significantly lower than in
the group treated with vehicle (14.75%  3.8%; n  4). Vessel
growth stimulated by IL-1 micropellets was more marked
than vessel growth stimulated by VEGF-A. Nonetheless, treat-
ment with ATLa (BV density: 16.1%  3.0%; n  4), RvD1 (BV
density: 17.1%  2.4%; n  4), or RvE1 (BV density: 18.6% 
2.2%; n  4) significantly impaired IL-1–induced BV growth
compared with vehicle treatment (BV density: 26.8%  2.0%;
n  4). Interestingly, and corroborating our previous observa-
tions in suture-induced CNV, no significant reduction of LA
stimulated by either IL-1 or VEGF-A was observed with any of
these mediator treatments (Fig. 6).
DISCUSSION
Here we report that the lipid mediators ATLa, RvD1, and
RvE1—in addition to their resolving effects on innate immu-
nity—regulate VEGF-A/-C and VEGFR2 and, as a result, signifi-
cantly reduce the development of NV in the inflamed cornea.
We also report that corneal tissues and infiltrating innate im-
mune cells express Fpr-rs2 (the LXA4 receptor) and ChemR23
(the RvE1 receptor), the ligation of which directly suppresses
angiogenesis. In the aggregate, these results in a model of
surgically induced corneal inflammation and angiogenesis con-
firm the functions of ATLa, RvD1, and RvE1 as potent dual
anti-inflammatory and pro-resolution molecules that can also
effectively stop angiogenesis.
The neutrophil is the most prominent and earliest cell to
migrate to the cornea in the early stages of inflammation,
and anti-inflammatory lipid mediators can promote resolu-
tion by shortening the duration of neutrophil tissue infiltra-
tion.25 In line with this current understanding, we show
here that the administration of ATLa, RvD1, and RvE1 indeed
blocked neutrophil infiltration of the cornea at 24 hours and
72 hours after insult, coinciding with the downregulation of
proinflammatory cytokine (e.g., TNF-, IL-1-, and IL-1-)
expression known to be secreted by innate immunocytes,
FIGURE 3. Resolvins and lipoxin re-
duce cytokine mRNA expression in
inflamed corneas. ATLa, RvD1, RvE1,
or vehicle was subconjunctivally in-
jected at 0 hour and 48 hours after
suture placement. For each com-
pound treatment, corneas were har-
vested from a group of mice at 24
hours, from another group at 72
hours after suture placement, and
from normal untreated control cor-
neas (six corneas per group). mRNA
levels of inflammatory cytokines (in-
cluding IL-1, IL-1, and TNF-)
were determined by real-time PCR.
Data were normalized to GAPDH
mRNA, and values were expressed as
the fold change over normal control
corneas. Results represent the mean
( SEM) of three samples per group
(each sample consisted of two
pooled corneas), and data are repre-
sentative of two independent exper-
iments (*P  0.05, **P  0.001 vs.
vehicle-treated group; t-test).
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particularly neutrophils. Moreover, our data show that mac-
rophage infiltration is also reduced significantly after the
local administration of ATLa, RvD1, and RvE1. These results
highlight the importance of neutrophil infiltration in the
local chemotaxis of subsequent immunocyte populations
such as the macrophage. It has been shown that ATLa and
RvE1 can also increase macrophage phagocytosis (e.g., of
apoptotic neutrophils), and this may contribute to the res-
olution of inflammation after treatment.26 Taken together,
local administration of these lipid mediators to the cornea
FIGURE 4. The impact of resolvins
and lipoxin on mRNA. Expression of
VEGFs and VEGFRs in inflamed cor-
neas. ATLa, RvD1, RvE1, or vehicle
was subconjunctivally injected at 0
hour and 48 hours after suture place-
ment. For each compound treat-
ment, corneas were harvested from a
group of mice at 24 hours, from an-
other group at 72 hours after suture
placement, and from normal un-
treated control corneas (six corneas
per group). (A) VEGF ligand species
(VEGF-A, VEGF-C, VEGF-D) and (B)
VEGFRs (VEGFR2 and VEGFR3)
were tested by real-time PCR and
normalized to GAPDH mRNA. Values
are expressed as fold change over
the normal control cornea. Results
represent the mean ( SEM) of three
samples per group (each sample
consisted of two pooled corneas),
and the data are representative of
two independent experiments (*P 
0.05, **P  0.001, ***P  0.0005 vs.
vehicle-treated group; t-test).
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control local innate immune cell infiltration and enhance the
resolution of inflammation.
Although the healthy or normal cornea is avascular, local
inflammation can stimulate the ingrowth of neovessels from
the surrounding limbal and conjunctival areas through the
secretion of proangiogenesis factors by local vascular endothe-
lial and inflammatory cells. Cytokines such as IL-1, IL-1, and
TNF-, are known to enhance the expression of angiogenic
factors.27–29 Among all the angiogenic factors, the VEGF spe-
cies play a pivotal role in vascular development. Ligation of
VEGFR2 by VEGF-A is critical in vascular EC proliferation and
differentiation in hemangiogenesis. On the other hand, binding
FIGURE 5. Suture-induced corneal
HA is reduced with resolvins and li-
poxin. ATLa, RvD1, RvE1, or vehicle
was subconjunctivally injected every
48 hours from 0 to 14 days after
suture placement. (A) In a masked
fashion, CNV was scored biomicro-
scopically with a slit lamp using a
grid system. Values are expressed as
the mean ( SEM) of six corneas. (B)
Whole corneal tissues were har-
vested on day 14 and were double
stained with anti–CD31 (green) and
anti–LYVE-1 (red) for epifluorescence
microscopy (20 magnification).
(C) The density of blood vessels
(CD31high/LYVE-1low) or lymphatic
vessels (CD31lowLYVE-1high) cover-
ing the cornea was analyzed. Values
are expressed as the mean ( SEM)
of six corneas per treatment group
(**P 0.001 vs. vehicle-treated group;
t-test), and the data are representative
of two independent experiments.
IOVS, October 2009, Vol. 50, No. 10 Novel Lipid Mediator Inhibition of Angiogenesis 4749
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933243/ on 06/18/2017
of VEGF-C/-D to VEGFR3 stimulates the development of lym-
phatic vessels. In addition, VEGF-C can bind to and activate
VEGFR230,31 and thereby contribute to HA, despite having
weaker binding affinity than VEGF-A.32 Interestingly, we found
that treatments with ATLa, RvD1, or RvE1 significantly reduced
the gene expression levels of VEGF-A, VEGF-C, and their re-
ceptor VEGFR2 but not of VEGF-D or VEGFR3. This indicates
that such treatments selectively regulate HA rather than LA, a
finding further supported by immunohistochemistry. Future
work will have to further delineate why ATLa, RvD1, and RvE1
lipid mediators differentially regulate VEGF species and recep-
tors.
Although IL-1 secretion can stimulate VEGF expression and
thereby promote angiogenesis, the administration of exoge-
nous VEGF-A can achieve a similar effect (possibly indepen-
dently of other downstream effectors resulting from IL-1 sig-
naling). Therefore, we questioned whether the suppression of
CNV by ATLa, RvD1, and RvE1 results from the suppression of
IL-1 or VEGF-A stimulation. The contribution of RvD1 and
RvE1 to the regulation of angiogenesis through the suppression
of TNF- expression has been reported based on a hypoxia-
induced pathologic retinal NV mouse model.33 Here we show
that RvD1 and RvE1 efficiently reduce IL-1–induced, but not
VEGF-A–induced, corneal angiogenesis. This suggests that the
antiangiogenesis function of RvD1 and RvE1 largely depends
on their anti-inflammatory/pro-resolution function rather than
on the direct regulation of VEGF-A function. This is further
supported by the reduction of macrophage infiltration ob-
served in IL-1–induced corneal angiogenesis with RvE1 and
RvD1 treatment.34
Interestingly, however, our results indicated that ATLa treat-
ment reduced not only IL-1–induced corneal angiogenesis but
also that induced by VEGF stimulation. The exclusive ability to
suppress VEGF-A–induced angiogenesis by ATLa treatment
could, in part, result from impairment in the early stage of EC
migration.35 Compared with other treatments, ATLa is thought
FIGURE 6. ATLa, RvD1, and RvE1
regulate IL-1– and VEGF-A–induced
corneal HA and LA. Hydron pellets
containing IL-1 or VEGF-A were im-
planted in the corneas on day 0.
ATLa, RvD1, RvE1, or vehicle was
subconjunctivally injected every 48
hours from 0 to 7 days after pellet
implantation (four corneas per treat-
ment for each pellet type). (A) Slit
lamp examination was performed on
day 7, and representative images are
shown. (B) The density of blood ves-
sels (CD31high/LYVE-1low) or lym-
phatic vessels (CD31lowLYVE-1high)
covering each cornea was analyzed.
Values are expressed as the mean (
SEM) of each treatment group (four
corneas per group), and the data are
representative of two independent
experiments (*P  0.05 vs. vehicle-
treated group; t-test).
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to be active for a longer duration because it is a stable analog
of LXA4/ATL, which resists local inactivation.36 Moreover,
ATLa exerts its inhibitory effects on multiple steps of VEGF-A–
induced angiogenesis, such as the inhibition of EC adhe-
sion37,38 and the suppression of VEGF-A–induced EC prolifer-
ation.39 These factors explain the actions of ATLa and its
demonstrably higher potency in suppressing angiogenesis
compared with the synthetic forms of RvD1 and RvE1.
The anti-inflammation and pro-resolution functions of LXA4
are related to the receptor ALX/FPRL1, which has been iden-
tified on neutrophils, monocytes, macrophages, dendritic cells,
epithelial cells, and keratocyte in humans. This function is
subserved by multiple receptors in the murine system, includ-
ing Lxa4r/Fprl1 and Fpr-rs2, which share 89% and 83% homol-
ogy at the nucleotide and protein levels, respectively.37
ChemR23, a receptor for RvE1 involved in the attenuation of
TNF-–activated NF-B, is abundantly expressed in macro-
phages and dendritic cells but less so in neutrophils.18,40 Our
present findings demonstrate that Fpr-rs2 and ChemR23, but
not Lxa4r/Fprl1, are expressed by the infiltrating CD11b cells
(which include macrophages, monocytic dendritic cells, and a
subset of neutrophils) in the cornea. These results suggest that
ATLa activation of Fpr-rs2 and RvE1 activation of ChemR23 on
these CD11b immunocytes stops their local migration and
cytokine production into the cornea.
Finally, though the expression of ALX in the cornea has
been implicated in epithelial cell proliferation in a wound-
healing model,41,42 the location of ALX in the cornea has not
been established to date. Here, for the first time, we distin-
guished the distributions of Fpr-rs2 and ChemR23 in the cor-
nea, which include epithelial cells and stromal keratocytes in
normal and inflammatory conditions. In conclusion, ATLa,
RvD1, and RvE1 effectively resolve corneal inflammation and
angiogenesis by controlling innate inflammation by marked
reduction of proinflammatory cytokine secretion and inhibit-
ing VEGF/VEGFR expression. These novel lipid mediators offer
a potentially new therapeutic strategy for controlling corneal
angiogenesis, a leading cause of blindness worldwide.
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